Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral Breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.

Article  CAS  PubMed  Google Scholar 

Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral oophorectomy and the risk of Breast Cancer in BRCA1 mutation carriers: a reappraisal. Cancer Epidemiol Biomarkers Prev. 2022;31:1351–8.

Article  CAS  PubMed  Google Scholar 

Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks Associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40:1529–41.

Article  PubMed  PubMed Central  Google Scholar 

Gao C, Polley EC, Hart SN, Huang H, Hu C, Gnanaolivu R, et al. Risk of Breast Cancer among carriers of pathogenic variants in Breast Cancer predisposition genes varies by polygenic risk score. J Clin Oncol. 2021;39:2564–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, et al. CanRisk Tool-A web interface for the prediction of breast and Ovarian Cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev. 2021;30:469–73.

Article  CAS  PubMed  Google Scholar 

Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, et al. A comparison of Ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecol Oncol. 2019;155:270–4.

Article  CAS  PubMed  Google Scholar 

Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, et al. Hereditary Ovarian Cancer Clinical Study Group. Contraceptive use and the risk of Ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2022;164:514–21.

Article  CAS  PubMed  Google Scholar 

Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–53.

Article  PubMed  PubMed Central  Google Scholar 

Lheureux S, Karakasis K, Oza AM. How to assess the potential interest of aspirin in Ovarian cancer? Cancer Epidemiol. 2015;39:790–1.

Article  CAS  PubMed  Google Scholar 

Narod SA. Modifiers of risk of hereditary Breast cancer. Oncogene. 2006;25:5832–6.

Article  CAS  PubMed  Google Scholar 

Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int J Cancer. 2015;137:1729–38.

Article  CAS  PubMed  Google Scholar 

Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M. Incidence of occult Breast Cancer in carriers of BRCA1/2 or other high-penetrance pathogenic variants undergoing prophylactic mastectomy: when is Sentinel Lymph Node Biopsy indicated? Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11916-3.

Article  PubMed  PubMed Central  Google Scholar 

Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J, extended ERN-GENTURIS Thematic Group 3. ;. Overview of hereditary breast and Ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet 202; 164:104350.

Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;46:30–47.

Google Scholar 

Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/Familial High-Risk Assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77–102.

Article  CAS  PubMed  Google Scholar 

Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP. The fallopian tube, precursor Escape and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol. 2019;152:426–33.

Article  PubMed  Google Scholar 

Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015; 107.

Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, GENEPSO, Noguès C, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and Breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020;22:8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, et al. Association of risk-reducing Surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on Survival after Breast Cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–13.

Article  PubMed  Google Scholar 

Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for Breast cancer patients with a BRCA1 mutation. Breast Cancer Res Treat. 2018;168:513–21.

Article  CAS  PubMed  Google Scholar 

Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, et al. The spectrum of BRCA1 and BRCA2 mutations in Breast cancer patients in the Bahamas. Clin Genet. 2014;85:64–7.

Article  CAS  PubMed  Google Scholar 

Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hereditary Breast Cancer Clinical Study Group. Hormone replacement therapy after oophorectomy and Breast Cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4:1059–65.

Article  PubMed  PubMed Central  Google Scholar 

Heemskerk-Gerritsen B, Jager A, Koppert L, Obdeijn A, Collée M, Meijers-Heijboer H, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177:723–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P. Increased overall mortality even after risk reducing Surgery for BRCA-Positive women in Western Sweden. Genes (Basel). 2019;10:1046.

Article  PubMed  Google Scholar 

Warner E, Zhu S, Plewes DB, Hill K, Ramsay EA, Causer PA et al. Breast Cancer mortality among women with a BRCA1 or BRCA2 mutation in a magnetic resonance Imaging Plus Mammography Screening Program. Cancers (Basel). 2020; 12.

US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M. Medication use to reduce risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322:857–67.

Article  Google Scholar 

Singer CF. Nonsurgical Prevention Strategies in BRCA1 and BRCA2 mutation carriers. Breast Care (Basel). 2021;16:144–8.

Article  PubMed  Google Scholar 

Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. Hereditary Breast Cancer Clinical Study Group. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121:15–21.

Article  PubMed  PubMed Central  Google Scholar 

Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral Breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT et al. Hereditary Breast Cancer Clinical Study Group. Duration of tamoxifen use and the risk of contralateral Breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014:421–7.

Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, Singer CF, Eisen A, Tung N, Olopade O, Bordeleau L, Eng C, Foulkes WD, Neuhausen SL, Cullinane CA, Pal T, Fruscio R, Lubinski J, Metcalfe K, Sun P, Narod SA. And the Hereditary Breast Cancer Clinical Study Group. Tamoxifen and the risk of Breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023;201(2):257–64.

Article  CAS  PubMed  Google Scholar 

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova, et al. MRANKL/RANK control Brca1 mutation. Cell Res. 2016;26:761–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sigl V, Jones LP, Penninger JM. RANKL/RANK: from bone loss to the prevention of Breast cancer. Open Biol. 2016;6:160230.

Article  PubMed  PubMed Central  Google Scholar 

Kotsopoulos J, Singer C, Narod SA. Can we prevent BRCA1-associated Breast cancer by RANKL inhibition? Breast Cancer Res Treat. 2017;161:11–6.

Article  CAS  PubMed  Google Scholar 

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Rohrbach K, et al. RANK ligand as a potential target for Breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016;22:933–9.

Article  CAS  PubMed  Google Scholar 

Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, et al. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet. 2015;88:182–6.

Article  CAS  PubMed  Google Scholar 

Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR. The screen project: guided Direct-To-Consumer genetic testing for Breast Cancer susceptibility in Canada. Cancers. 2021;15:1894.

Article  Google Scholar